| Company | Sector & Purpose | Updated | Following |
|---|---|---|---|
|
Abbvie
|
Biopharmaceutical
To discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow
|
2025-Q2
|
|
|
Abbott Laboratories
|
Healthcare
To help people live their best possible life through the power of health
|
2025-Q3
|
|
|
Amicus Therapeutics
|
Biotechnology
To serve patients, families and caregivers affected by rare and orphan diseases
|
2025-Q3
|
|
|
Aldeyra Therapeutics
|
Biotechnology
To discover, develop and commercialize novel therapies to treat immune-mediated diseases
|
2025-Q3
|
|
|
Acadia Pharmaceuticals
|
Biopharmaceuticals
To advance breakthrough medicines that meaningfully improve the lives of patients with central nervous system disorders
|
2025-Q3
|
|
|
Agios Pharmaceuticals
|
Biopharmaceutical
To transform the lives of patients with genetically defined diseases through scientific leadership in cellular metabolism
|
2025-Q3
|
|
|
Anika Therapeutics
|
Biotechnology
To develop and commercialize therapeutic products for tissue protection, healing, and repair
|
2025-Q3
|
|
|
Akebia Therapeutics
|
Biopharmaceutical
To better the lives of people impacted by kidney disease by advancing innovative therapies
|
2025-Q3
|
|
|
Amphastar Pharmaceuticals
|
Specialty Pharmaceuticals
To develop, manufacture, and market generic and proprietary injectable, inhalation, and intranasal pharmaceutical products
|
2025-Q3
|
|
|
Alector
|
Biotechnology
To develop innovative immunotherapies for neurodegenerative diseases by harnessing the brain's immune system
|
2025-Q3
|
|
|
Absci
|
Biotechnology
To create better biologics through the power of artificial intelligence and synthetic biology
|
2025-Q3
|
|
|
Ani Pharmaceuticals
|
Specialty Pharmaceuticals
To develop, manufacture and market branded and generic prescription pharmaceuticals
|
2025-Q3
|
|
|
Alkermes
|
Biopharmaceuticals
To develop innovative medicines that make a difference for people living with debilitating diseases
|
2025-Q3
|
|
|
Anaptysbio
|
Biotechnology
To discover, develop and deliver innovative immunology therapeutics for patients with serious immune-mediated diseases
|
2025-Q3
|
|
|
Amneal Pharmaceuticals
|
Generic Pharmaceuticals
To make healthy possible by providing high-quality, affordable generic and specialty pharmaceuticals to improve patient access to essential medications
|
2025-Q3
|
|
|
Altimmune
|
Biotechnology
To develop innovative medicines for obesity, NASH, and metabolic diseases
|
2025-Q3
|
|
|
Anavex Life Sciences
|
Biopharmaceutical
Develop precision medicine therapies targeting sigma-1 receptor for neurodegenerative diseases
|
2025-Q3
|
|
|
89bio
|
Biotechnology
To develop innovative therapies for patients with liver and cardio-metabolic diseases
|
2025-Q3
|
|
|
Akero Therapeutics
|
Biotechnology
To develop and commercialize transformational treatments for patients with serious metabolic diseases
|
2025-Q3
|
|
|
Alumis
|
Biotechnology
To develop transformative medicines for autoimmune and inflammatory diseases through precision targeting of key immune pathways
|
2025-Q3
|
Page 1 of 2
Showing 1 to 20 of 37 analyses